ReviewAutoimmunity reviews2005
Improved approach to identify cancer-associated autoantigens.
Review in Autoimmunity reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Five autoantibodies identified from immune complexes as breast cancer biomarkers.Frontiers in immunology · 2025Article
- Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease.Glycobiology · 2023Review
- Muscarinic Receptors Associated with Cancer.Cancers · 2022Review
- Autoantibodies against cytoskeletons and lysosomal trafficking discriminate sarcoidosis from healthy controls, tuberculosis and lung cancers.Molecular biomedicine · 2022Article
- Mitochondria Autoimmunity and MNRR1 in Breast Carcinogenesis: A Review.Journal of cancer immunology · 2020Article
- Integration of IgA and IgG Autoantigens Improves Performance of Biomarker Panels for Early Diagnosis of Lung Cancer.Molecular & cellular proteomics : MCP · 2020Article
- Preferential recognition of auto-antibodies against 4-hydroxynonenal modified DNA in the cancer patients.Journal of clinical laboratory analysis · 2017Article
- Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Aberrant Cosmc genes result in Tn antigen expression in human colorectal carcinoma cell line HT-29.International journal of clinical and experimental pathology · 2015Article
- Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma.Oncology reports · 2013Article
- Autoantibodies against muscarinic receptors in breast cancer: their role in tumor angiogenesis.PloS one · 2013Article
- Serologic laboratory findings in malignancy.Rheumatic diseases clinics of North America · 2011Review
- The Tn antigen-structural simplicity and biological complexity.Angewandte Chemie (International ed. in English) · 2011Review
- A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction.Glycobiology · 2009Article
- Autoantibodies to tumor-associated antigens: reporters from the immune system.Immunological reviews · 2008Review
- Tumor-associated antigen arrays for the serological diagnosis of cancer.Molecular & cellular proteomics : MCP · 2006Review
- Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The failure to identify biomarkers of clinical significance for cancer diagnosis and prognosis generated a great deal of skepticism in regard to the usefulness of autoantibody-based methods. SEREX was a major advancement in immunoscreening that resulted in the identification of a large group of autoantigens recognized by cancer sera. However, few SEREX-defined autoantigens have proven to have definitive diagnostic value in clinical practice. Often, the identified antigens are patient-specific rather than tumor-specific and many tumor-associated antigens are rare in expression libraries made from non-autologous cells. Since autoantibodies are part of the normal immune response, it can be difficult to single out tumor-associated antibodies from the scores of irrelevant patient-specific responses. In our view, any practical approach for identifying cancer-related autoantigens must include an integral strategy for demonstrating tumor relevance early in the screening process. Care must also be taken not to exclude potentially important autoantibodies by pre-screening manipulations to patient sera. We have introduced substantial modifications in SEREX, designed to minimize confounding effects of unrelated autoantibodies and to eliminate steps that preclude the identification of cancer-related autoantigens commonly recognized by cancer sera. In addition, we incorporate methodology to identify candidate antigens that have potential diagnostic or prognostic value prior to their molecular cloning and characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.